MANGALAM DRUG & CHEM Latest Share Price (MANGALAM)
TODAY IN ONE LINE
MANGALAM slipped 0.9% on average volume, lagging Nifty's 0.1% move.
With a market cap of ₹47.96 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MANGALAM DRUG & CHEM flags & news
Key strengths, potential risks, and recent updates.
Green Flags
No green flags identified
Red Flags
- ●Promoter SellingPromoter holding decreased by 35.65% QoQ
- ●Promoter Pledging DetectedPledge activity recorded on 14-Aug-2025 18:07
Latest MANGALAM DRUG & CHEM News
What changed recently?
Recent events, corporate actions, and announcements.
MANGALAM DRUG & CHEM valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MANGALAM DRUG & CHEM, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MANGALAM DRUG & CHEM technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MANGALAM DRUG & CHEM — derived from the latest tape, not yesterday's close.
MANGALAM DRUG & CHEM last traded at ₹30.02 with an intraday range of ₹29.9–₹30.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹30.02| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 32.65 | +2.63 | +8.75% |
| R3 | 31.65 | +1.63 | +5.42% |
| R2 | 31.27 | +1.25 | +4.17% |
| R1 | 30.65 | +0.63 | +2.09% |
| PIVOT | 30.27 | 0.25 | 0.84% |
| CURRENT | 30.02 | — | — |
| S1 | 29.65 | -0.37 | -1.24% |
| S2 | 29.27 | -0.75 | -2.49% |
| S3 | 28.65 | -1.37 | -4.57% |
| S4 | 27.65 | -2.37 | -7.91% |
MANGALAM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹30.3–₹30.9
Trading Inside opening range
MANGALAM DRUG & CHEM financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MANGALAM DRUG & CHEM — consolidated or standalone — with margins, YoY growth and key ratios inline.
MANGALAM DRUG & CHEM reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹47.96 Cr. and reported EPS of ₹-4.83.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 318 | 232 ▼ 27.1% |
| Sales Growth YoY %Derived | -13.66% | -27.06% |
| Other Income | 1 | 1 ▲ 51.8% |
| Total Income | 319 | 233 ▼ 26.9% |
| 167 | 157 ▼ 6.3% | |
| Gross ProfitDerived | 151 | 75 ▼ 50.1% |
| Gross Margin %Derived | 47.41% | 32.42% |
| 115 | 90 ▼ 21.6% | |
| EBITDA (Operating Profit)Derived | 36 | -15 ▼ 141.6% |
| OPM %Derived | 11.26% | -6.42% |
| 32 | 34 ▲ 9.2% | |
| Profit Before Tax (PBT) | 5 | -49 ▼ 1114.9% |
| -2 | -4 ▼ 115.6% | |
| Effective Tax %Derived | -40.43% | 8.59% |
| Total Profit for Period | 7 | -44 ▼ 760.6% |
| Net Profit (Owner's PAT)Derived | 7 | -44 ▼ 760.6% |
| Net Profit Margin %Derived | 2.11% | -19.13% |
| PAT Growth YoY %Derived | 174.08% | -760.65% |
| Earnings Per Share (EPS ₹) | 4.25 | -28.05 ▼ 760.0% |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 6 | -0 ▼ 107.0% |
| Total Expenses (incl. D&A & Interest) | 314 | 281 ▼ 10.3% |
| Material Cost % of RevenueDerived | 53.60% | 53.76% |
| Employee Cost % of RevenueDerived | 12.75% | 14.56% |
| Other Cost % of RevenueDerived | 23.40% | 24.28% |
| Interest Coverage (x)Derived | 1.29x | -2.04x |
| Period | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|
| Revenue from Operations | 369 | 318 ▼ 13.7% | 232 ▼ 27.1% | |
| Sales Growth YoY %Derived | — | -13.66% | -27.06% | |
| Other Income | 0 | 1 ▲ 412.9% | 1 ▲ 51.8% | |
| Total Income | 369 | 319 ▼ 13.6% | 233 ▼ 26.9% | |
245 | 167 ▼ 31.6% | 157 ▼ 6.3% | ||
| Gross ProfitDerived | 124 | 151 ▲ 21.6% | 75 ▼ 50.1% | |
| Gross Margin %Derived | 33.66% | 47.41% | 32.42% | |
107 | 115 ▲ 7.8% | 90 ▼ 21.6% | ||
| EBITDA (Operating Profit)Derived | 17 | 36 ▲ 105.9% | -15 ▼ 141.6% | |
| OPM %Derived | 4.72% | 11.26% | -6.42% | |
29 | 32 ▲ 10.4% | 34 ▲ 9.2% | ||
| Profit Before Tax (PBT) | -11 | 5 ▲ 143.2% | -49 ▼ 1114.9% | |
-2 | -2 ▲ 3.3% | -4 ▼ 115.6% | ||
| Effective Tax %Derived | 18.08% | -40.43% | 8.59% | |
| Total Profit for Period | -9 | 7 ▲ 174.1% | -44 ▼ 760.6% | |
| Net Profit (Owner's PAT)Derived | -9 | 7 ▲ 174.1% | -44 ▼ 760.6% | |
| Net Profit Margin %Derived | -2.46% | 2.11% | -19.13% | |
| PAT Growth YoY %Derived | — | 174.08% | -760.65% | |
| Earnings Per Share (EPS ₹) | -5.73 | 4.25 ▲ 174.2% | -28.05 ▼ 760.0% | |
| Diluted Shares Outstanding (Cr) | 2 | 2 ▲ 0.0% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | 6 ▲ 1255.2% | -0 ▼ 107.0% | |
| Total Expenses (incl. D&A & Interest) | 380 | 314 ▼ 17.3% | 281 ▼ 10.3% | |
| Material Cost % of RevenueDerived | 60.98% | 53.60% | 53.76% | |
| Employee Cost % of RevenueDerived | 10.60% | 12.75% | 14.56% | |
| Other Cost % of RevenueDerived | 18.34% | 23.40% | 24.28% | |
| Interest Coverage (x)Derived | 0.20x | 1.29x | -2.04x |
MANGALAM DRUG & CHEM segment analysis : revenue and profit mix.
Disclosed business segments at MANGALAM DRUG & CHEM with their share of revenue and profit, switchable between consolidated and standalone reporting.
MANGALAM DRUG & CHEM discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MANGALAM DRUG & CHEM.
Our AI distills the core fundamental drivers supporting MANGALAM DRUG & CHEM, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
MANGALAM DRUG & CHEM's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Trading significantly below book value at P/B 0.46, offering deep value entry point.
Debt-to-equity ratio 0.01x indicates manageable leverage relative to equity base.
Positive operating cash flow ₹7.71 Cr in latest quarter generates liquidity despite losses.
Free cash flow ₹1.91 Cr in Q3 FY2025 demonstrates cash generation ability amid operational stress.
Growing pharmaceutical demand globally positions API sector for expansion and market growth.
Key Risks.
Operating margin deeply negative at -13.66% quarterly, indicating severe operational inefficiency.
ROE -42.41% reflects poor shareholder value creation and significant capital destruction.
TTM revenue growth -7.50% YoY signals sustained demand contraction in core API markets.
Total debt ₹102.06 Cr exceeds market cap ₹48.32 Cr, creating extreme solvency risk.
Latest quarterly EPS -₹4.83 versus ₹0.06 prior year reflects extreme earnings deterioration.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.49. Balance sheet risk re-prices growth multiples fast.
MANGALAM DRUG & CHEM peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MANGALAM DRUG & CHEM is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MANGALAM DRUG & CHEM chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MANGALAM DRUG & CHEM — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MANGALAM DRUG & CHEM delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MANGALAM DRUG & CHEM over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MANGALAM DRUG & CHEM stood at 73.9% of traded volume, against a 20-day average of 68.3%.
MANGALAM DRUG & CHEM announcements: results, concalls, ratings, M&A.
Filings MANGALAM DRUG & CHEM sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MANGALAM DRUG & CHEM files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 79 documents below.
Copy of Newspaper Publication
Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Mangalam Drugs And Organics Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 23, 2026
Fraud/Default/Arrest
Mangalam Drugs And Organics Limited has informed the Exchange about Fraud/Default/Arrest
Copy of Newspaper Publication
Mangalam Drugs And Organics Limited has informed the Exchange about Copy of Newspaper Publication
Change in Auditors
Mangalam Drugs And Organics Limited has informed the Exchange regarding Change in Auditors of the company.
Investor decks & rating reports.
MANGALAM DRUG & CHEM dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MANGALAM DRUG & CHEM has declared, sequenced by announce and record date.
MANGALAM DRUG & CHEM corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
MANGALAM DRUG & CHEM insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in MANGALAM DRUG & CHEM as reported to SEBI — buying and selling signals from the people who know the business best.
MANGALAM DRUG & CHEM insider activity below tracks 11 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| ADITYA RAMNIWAS DHOOT | Insider | 16 Mar 2026 | buy | +89.0 K | — | — |
| SHREE RASBIHARI TRADING AND INVESTMENTS PRIVATE LIMITED | Insider | 16 Mar 2026 | buy | +1.73 L | ₹54.86 L | ₹31.71 |
| AJAY RAMNIWAS DHOOT | Insider | 16 Mar 2026 | buy | +1.38 L | — | — |
| SHREE KISHORIJU TRADING AND INVESTMENT PRIVATE LIMITED | Insider | 06 Feb 2026 | buy | +1.5 K | ₹51,465 | ₹34.31 |
| SHREE KISHORIJU TRADING AND INVESTMENT PRIVATE LIMITED | Insider | 06 Feb 2026 | buy | +1.5 K | ₹51,465 | ₹34.31 |
| SHREE KISHORIJU TRADING AND INVESTMENT PRIVATE LIMITED | Insider | 06 Feb 2026 | buy | +1.5 K | ₹51,465 | ₹34.31 |
| SHREE KISHORIJU TRADING AND INVESTMENT PRIVATE LIMITED | Insider | 06 Feb 2026 | buy | +1.5 K | ₹51,465 | ₹34.31 |
| SHREE KISHORIJU TRADING AND INVESTMENTS PRIVATE LIMITED | Insider | 05 Mar 2025 | buy | +1.53 L | ₹1.17 Cr. | ₹76.32 |
| Shree Kishoriju Trading and Investments Private Limited | Insider | 29 Jan 2025 | buy | +20.0 K | ₹20.26 L | ₹101.30 |
| SHREE KISHORIJU TRADING AND INVESTMENT PRIVATE LIMITED | Insider | 18 Jan 2025 | buy | +25.0 K | ₹26.48 L | ₹105.92 |
About MANGALAM DRUG & CHEM: business, sector, key facts.
What MANGALAM DRUG & CHEM does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MANGALAM DRUG & CHEM operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MANGALAM, BSE: 532637.
Mangalam Drugs & Organics Limited is an Indian company primarily engaged in the manufacturing and sale of active pharmaceutical ingredients (APIs) and intermediates. Their product portfolio is extensive and caters to a wide range of pharmaceutical applications.
A significant portion of their API business focuses on producing key components for various medications. This includes antivirals like acyclovir and efavirenz, antimalarials such as artemether and chloroquine phosphate, and other drugs used to treat diverse conditions. The specific APIs they produce are numerous and cover a broad therapeutic spectrum, highlighting their expertise in this area.
Beyond APIs, Mangalam also manufactures and supplies crucial intermediates used in the synthesis of other pharmaceuticals. These intermediates represent a critical step in the production chain, providing the building blocks for complex drug molecules. The company’s capabilities extend to the creation of both simple and complex chemical structures necessary for various pharmaceutical applications.
Furthermore, Mangalam's business extends to the production of specialty chemicals. These encompass diverse chemical compounds with applications beyond pharmaceuticals, demonstrating a broader chemical manufacturing capacity. Their involvement in developing novel compounds like tafenoquine succinate and pretomanid indicates a commitment to research and development within the pharmaceutical and specialty chemical sectors.
In addition to their core business of API, intermediate, and specialty chemical manufacturing, Mangalam also produces organic and inorganic chemicals, as well as heavy chemicals, showcasing a diverse manufacturing capability within the broader chemical industry. Established in 1972 and headquartered in Mumbai, the company's long history reflects a sustained presence and expertise in the Indian chemical manufacturing landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about MANGALAM DRUG & CHEM (MANGALAM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MANGALAM DRUG & CHEM (MANGALAM)?
The current share price of MANGALAM DRUG & CHEM (MANGALAM) is ₹30.02. Today, the stock has declined by ₹0.28 (0.92%), trading in a range of ₹29.90 to ₹30.90. The stock opened at ₹30.90 with a trading volume of 18,726 shares.
02What is the 52-week high and low price of MANGALAM DRUG & CHEM stock?
The 52-week high price of MANGALAM DRUG & CHEM (MANGALAM) is ₹79.70, while the 52-week low is ₹22.80. Currently trading at ₹30.02, the stock is 31.67% above its 52-week low and 62.33% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03What is the dividend yield of MANGALAM DRUG & CHEM and when is the next dividend?
MANGALAM DRUG & CHEM offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹30.02, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
04How is MANGALAM DRUG & CHEM stock performing today in the market?
MANGALAM DRUG & CHEM stock opened at ₹30.90 and is currently trading at ₹30.02, showing a decline of ₹0.28 (0.92%). The intraday high is ₹30.90 and low is ₹29.90. The trading volume stands at 18,726 shares, indicating moderate market participation today.
05What is the market capitalization of MANGALAM DRUG & CHEM?
MANGALAM DRUG & CHEM has a market capitalization of ₹47.96 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹30.02) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
06What is the ROE and ROCE of MANGALAM DRUG & CHEM?
MANGALAM DRUG & CHEM has a Return on Equity (ROE) of -42.41% and Return on Capital Employed (ROCE) of -15.52%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
07Which sector and industry does MANGALAM DRUG & CHEM belong to?
MANGALAM DRUG & CHEM operates in the Healthcare sector and belongs to the Pharmaceuticals industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
08What is the debt-to-equity ratio of MANGALAM DRUG & CHEM?
MANGALAM DRUG & CHEM has a debt-to-equity ratio of 0.99, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
The data, ratios and commentary about MANGALAM DRUG & CHEM (MANGALAM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.